The Pulmonary Hypertension Association (PHA) has expanded its Pulmonary Hypertension Care Centers (PHCC) network by accrediting two new pulmonary hypertension (PH) programs as Centers for Comprehensive Care (CCC). The two new additions, the Pulmonary Hypertension Programs at Cincinnati Children’s Hospital Medical Center, in Cincinnati, Ohio, and…
News
Pulmonary hypertension expert Paresh Giri believes in patient support groups. The prevailing view is that the groups’ main function is helping patients cope with their condition. They certainly do that, but their gatherings are also places where valuable information is exchanged, Giri said. “For example, to hear how one person…
The ratio between the proteins MMP2 and TIMP4 in blood samples of idiopathic pulmonary arterial hypertension (iPAH) patients was found to predict disease worsening and mortality in a German study. It also correlated with mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance, and other indicators of disease progression. The study, “…
The U.S. Food and Drug Administration (FDA) agreed to the Phase 2 study of INOpulse in pulmonary hypertension (PH) patients with interstitial lung disease. This is the third potential treatment application of INOpulse, a device that delivers inhaled nitric oxide, developed by Bellerophon Therapeutics. In patients with pulmonary…
The Phase 4 multicenter, observational PaTTerN registry evaluating the use of Inomax (nitric oxide) in newborns with pulmonary hypertension (PH) has enrolled its first patient, Mallinckrodt Pharmaceuticals announced. The registry (NCT03132428) is actively recruiting participants, said the British drug conglomerate. Persistent PH in newborns is a serious, sometimes fatal, condition marked by increased pulmonary vascular pressure.
A new study shows that CMR (cardiovascular magnetic resonance) fluoroscopy-guided heart catheterization is a safe method with an appropriate procedure time, high rate of success, and better accuracy than the more commonly used techniques to determine hemodynamic parameters. The study, titled, “CMR fluoroscopy right heart catheterization for cardiac…
Adcirca (tadalafil) showed an acceptable safety profile and effectiveness in a real-world clinical cohort of pediatric patients with pulmonary arterial hypertension (PAH) in Japan. The study, “Safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial…
Complexa has obtained $62 million in financing to continue advancing its pulmonary arterial hypertension therapy CXA-10 through the clinical trial process. The company is also developing CXA-10 as a treatment for kidney disease focal segmental glomerulosclerosis, or FSGS. Companies that participated in Complexa’s third round of financing included New Enterprise…
The survival rate of pulmonary hypertension patients who received heart and lung transplants increased after France began giving transplant priority to those experiencing life-threatening episodes, a study reports. The high-priority list covered PH patients who had signed up for heart-lung transplants, or HLTs, and double lung transplants, or  DLTs. Researchers published…
Long-term Prostacyclin Use Increases Risk of a Heart Problem After a Lung Transplant, Study Reports
Pulmonary hypertension patients who receive prostacyclin for a long time are at higher risk of developing cardiovascular complications after a lung transplant, a Japanese study reports. The research, published in the International Heart Journal, was titled “High Frequency of Acute Adverse Cardiovascular Events After Lung Transplantation in Patients…
Two Pulmonary Hypertension Groups Sign Up for ZappRx’s Streamlined Prescription-ordering Service
Two pulmonary hypertension treatment groups are now working with a company that helps doctors to streamline the complex process of obtaining insurance company sign-offs on speciality prescriptions, which can take weeks. Arizona Pulmonary Specialists in Phoenix and the pulmonary hypertension unit at Harbor-UCLA Medical Center in Torrance, California, have become clients of  ZappRx. The process…
Obese people with pulmonary arterial hypertension (PAH) are less likely than patients of normal weight to die while hospitalized, finds a study examining the so-called “obesity paradox.” The study, “Relation Between Obesity and Survival in Patients Hospitalized for Pulmonary Arterial Hypertension (from a Nationwide Inpatient Sample Database 2003 to…
Recent Posts
- Issues with tiny heart blood vessels may contribute to damage in PAH
- New AI model uses retinal images to help predict PH risk in infants
- New Phase 3 trial data show ralinepag met main goal in PAH treatment
- Deal worth nearly $1B gets GSK potential best-in-class PH treatment
- How I transitioned from an IV therapy pump to oral meds
